<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543022</url>
  </required_header>
  <id_info>
    <org_study_id>184916</org_study_id>
    <nct_id>NCT01543022</nct_id>
  </id_info>
  <brief_title>Symphony: The Implantable Counter Pulsation Device (CPD) Safety and Feasibility Trial</brief_title>
  <acronym>Symphony</acronym>
  <official_title>First in Man Study - a Prospective, Multicenter, Single Arm Trial to Investigate the Safety and Feasibility of the Symphony Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abiomed Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abiomed Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Counter Pulsation Device (CPD) System 'Symphony' is intended to provide counter pulsation&#xD;
      therapy for up to thirty (30) days to patients with chronic heart failure who have persistent&#xD;
      worsening of their condition despite optimal medical therapy. Patients will be in New York&#xD;
      Heart Association (NYHA) Class IIIb or IV heart failure and have exhausted all medical or&#xD;
      surgical options.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death, Stroke or Transient Ischemic Attack (TIA), Limb Ischemia requiring surgical intervention</measure>
    <time_frame>hospital discharge or 30 days of support, whichever is longer</time_frame>
    <description>The trial will primarily look at patient safety defined as proportion of composite Major Adverse Events (MAE) up to hospital discharge or 30 days of CPD support, whichever is longer.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Symphony system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Symphony</intervention_name>
    <description>The Symphony system has been developed for superficial implantation without the need to enter the chest. It allows for complete patient mobility and provides counter pulsation therapy for up to 30 days in hospitalized patients.</description>
    <arm_group_label>Symphony system</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>The operative approach is limited to an infraclavicular incision similar to that used for placement of a pacemaker</intervention_name>
    <description>The vascular graft is surgically attached (anastomosed) to the subclavian artery. The symphony device is implanted into a pocket below the pectoralis muscle on the anterior chest and attached to the graft. The driveline is tunneled out through the skin and attached to the drive console.</description>
    <arm_group_label>Symphony system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. New York Heart Association Class IIIB or IV heart failure despite optimal medical&#xD;
             therapy, including ACE inhibitors, beta blockers, IV diuretics and pressors&#xD;
&#xD;
          2. Left Ventricular Ejection Fraction &lt; 40%.&#xD;
&#xD;
          3. Patient is not a candidate for conventional catheter-based or surgical intervention&#xD;
             such as valve intervention or coronary artery bypass surgery.&#xD;
&#xD;
          4. Patient is not currently a candidate for heart transplantation or placement of a left&#xD;
             ventricular assist device (LVAD) as bridge to heart transplantation due to&#xD;
             co-morbidities. Patients may become a candidate for these options if they have&#xD;
             improvement on the device due to improved cardiac output.&#xD;
&#xD;
          5. Patients have exhausted all approved surgical and medical therapies as determined by a&#xD;
             heart failure cardiologist and a surgeon with expertise in heart failure.&#xD;
&#xD;
          6. Patient has been evaluated by a multi-disciplinary research team and felt to be a&#xD;
             suitable candidate for a research study. The final decision regarding the patient's&#xD;
             candidacy for research will remain with the attending cardiologist and heart surgeon.&#xD;
&#xD;
          7. Improved hemodynamics on device support will allow for potential for physical&#xD;
             rehabilitation.&#xD;
&#xD;
          8. Signed Informed Consent, or oral informed consent with written confirmation by&#xD;
             uninvolved third party&#xD;
&#xD;
          9. Age of subject at least 19 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. High likelihood of death during the current hospitalization (as judged by the&#xD;
             attending physician) and condition other than heart failure that would limit survival&#xD;
             to less than two years.&#xD;
&#xD;
          2. Require mechanical ventilation.&#xD;
&#xD;
          3. Failure to wean from IABP, Impella, ECMO or other mode of circulatory support.&#xD;
&#xD;
          4. Complex arrhythmias that negatively impact the effectiveness of counter pulsation.&#xD;
&#xD;
          5. Dependency on high dose inotropes.&#xD;
&#xD;
          6. Cerebrovascular accident or TIA within the previous 3 months.&#xD;
&#xD;
          7. Contraindication to anticoagulation medication such as Heparin, Coumadin, Aspirin and&#xD;
             Plavix.&#xD;
&#xD;
          8. Presence of hypercoaguable state or history of idiopathic venous or arterial&#xD;
             thrombosis.&#xD;
&#xD;
          9. Severe calcification in the target vessel that will preclude insertion of the Symphony&#xD;
             device.&#xD;
&#xD;
         10. Moderate to severe aortic insufficiency (2+ or more).&#xD;
&#xD;
         11. Ongoing systemic infection defined as two of the following:&#xD;
&#xD;
               -  WBC &gt; 12,500&#xD;
&#xD;
               -  positive blood culture&#xD;
&#xD;
               -  fever&#xD;
&#xD;
         12. Abnormal pre-albumin (&lt; 13mg/dL), or albumin (&lt; 3.0 mg/dl)&#xD;
&#xD;
         13. A cardiac rhythm that cannot be used to trigger the CPD (sinus rhythm, ventricular or&#xD;
             atrial pacing, A-V pacing).&#xD;
&#xD;
         14. Abnormal bilateral carotid Doppler or CT exam define as &gt; 50% stenosis.&#xD;
&#xD;
         15. Subclavian artery internal diameter of &lt; 7 mm on Doppler study or CT exam.&#xD;
&#xD;
         16. Ability to ambulate &lt; 200 metres on a 6 minute walk test.&#xD;
&#xD;
         17. Any aortic aneurysmal disease.&#xD;
&#xD;
         18. Active documented HIT.&#xD;
&#xD;
         19. Presence of mechanical heart valve.&#xD;
&#xD;
         20. Moderate to severe RV failure.&#xD;
&#xD;
         21. Severe tricuspid regurgitation.&#xD;
&#xD;
         22. History of major psychiatric illness.&#xD;
&#xD;
         23. End-organ dysfunction including:&#xD;
&#xD;
               -  renal failure defined as serum Cr &gt; 2.5 mg/dl,&#xD;
&#xD;
               -  liver dysfunction defined as bilirubin 2X normal, or elevated INR with no&#xD;
                  anticoagulation,&#xD;
&#xD;
               -  respiratory failure defined as FEV1 &lt; 50% predicted.&#xD;
&#xD;
         24. Chest X-ray to rule out pulmonary pathology that increases the risk of need for&#xD;
             treatment prior to device implant.&#xD;
&#xD;
         25. BMI &gt; 40 kg/ m2.&#xD;
&#xD;
         26. Active participation in another clinical trial that may interfere with this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carol Loring</last_name>
    <phone>781-646-1595</phone>
    <email>cloring@abiomed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anson Cheung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Center, University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mackenzie A Quantz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Renzo Cecere, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>February 27, 2012</study_first_submitted>
  <study_first_submitted_qc>March 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2012</study_first_posted>
  <last_update_submitted>May 1, 2013</last_update_submitted>
  <last_update_submitted_qc>May 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

